Highest-materiality recent filing
Oscar Health elects 8 directors, approves say-on-pay and auditor at 2026 annual meeting
All eight director nominees elected with votes FOR ranging from 750M to 773M; broker non-votes ~46M.
Oscar Health to present at Goldman Sachs conference, reaffirms FY2026 guidance
Fireside chat at Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026 at 11:20 AM ET.
Oscar Health Co-Founder Schlosser transitions from CTO to Advisor to CEO
New role as Co-Founder & Advisor to CEO effective June 1, 2026; continues to serve on Board.
Oscar Health Q1 net income $679M ($2.07 EPS) vs $275M ($0.92) YoY; revenue $4.65B
Revenue $4.65B, up 53% YoY from $3.05B; net income $679M ($2.07 EPS) vs $275M ($0.92 EPS) YoY.
Oscar Health appoints new Board Chair, Siddhartha Sankaran, effective June 4
Siddhartha Sankaran appointed independent Chair of Board, effective June 4, 2026.
Oscar Health reaffirms FY 2026 guidance at Raymond James conference
Participating in the 2026 Raymond James Institutional Investors Conference on March 2, 2026.
Oscar Health reports record 3.4M members, FY2025 net loss $443M; guides FY2026 revenue $18.7-$19B
Full-year 2025 net loss $443.2M ($1.69 diluted EPS) vs prior-year net income $25.4M ($0.10 diluted EPS).
Oscar Health amends CEO Bertolini's employment agreement; $45M equity grant, base salary $1.3M
New term from Dec 22, 2025 to Apr 1, 2029, with automatic one-year renewals unless either party elects not to extend.
Oscar Health Q3 net loss $137.5M ($0.53 EPS); exchanges $187.5M notes for 23.3M shares
Q3 total revenue $2.99B (+23% YoY); net loss $137.5M vs $54.6M loss YoY; Adj EBITDA loss $101.5M vs $11.6M loss.
Oscar Health issues $410M of 2.25% convertible notes due 2030; net proceeds ~$395.8M
Notes carry 2.25% coupon, mature Sep 1, 2030; initial conversion price ~$24.82 per share.
Oscar Health prices $355M 2.25% convertible notes due 2030; uses proceeds for growth and AI
Upsized offering of $355M (from $350M); 2.25% interest, due September 1, 2030.
Oscar Health proposes $350M convertible notes due 2030; to fund AI, growth initiatives
$350M principal amount of convertible senior subordinated notes due 2030; underwriters option for additional $52.5M.
Oscar Health reaffirms FY2025 guidance at Wells Fargo conference
Reaffirmed updated full-year 2025 guidance first provided July 22, 2025.
Oscar Health Q2 net loss $228.4M, MLR 91.1% vs 79.0% YoY; revenue up 29%
Total revenue: $2.86B, up 29% YoY from $2.22B on higher membership, partly offset by risk adjustment accrual.
Oscar Health expects Q2 operating loss ~$230M; cuts FY2025 guidance on higher ACA risk scores
Q2 expects loss from operations of ~$230M and net loss of ~$228M.
All nine director nominees elected; highest vote FOR Mark T. Bertolini (804M), lowest Mario Schlosser (799M).
Oscar Health reports Q1 2025 revenue of $3.05B, net income $275M, and reaffirms full-year guidance
Total revenue rose 42% year-over-year to $3.046 billion for Q1 2025, driven by higher membership.
Oscar Health reaffirms FY2025 guidance at Raymond James conference
Company participates in 2025 Raymond James Institutional Investors Conference on March 3.
Total Revenue $9.2B (+56.5% YoY); Net income $25.4M ($0.10 diluted EPS) vs loss of $270.7M in 2023.
Oscar Health Q3 revenue $2.4B (+68% YoY); narrows loss; raises FY revenue guidance
Total revenue $2.4B, +68% YoY; net loss $54.6M ($0.22 EPS) improved $10.8M YoY.
Oscar Health to reaffirm FY2024 guidance at three investor conferences in Sept 2024
Company participates in Wells Fargo Conference Sept 4, Morgan Stanley Conference Sept 5, and Baird Conference Sept 11.
Oscar Health Q2 net income $56.2M, rev $2.2B +46% YoY, raises FY guidance
Net income of $56.2M ($0.20 diluted EPS) vs. loss of $15.5M a year ago.
Oscar Health holds 2024 Annual Meeting; all director nominees and proposals approved
Ten director nominees elected; top vote getter Mark T. Bertolini with 840.4M votes for.
Oscar Health reconfirms FY2024 guidance, to provide updated strategic targets at Investor Day
Reaffirms full-year 2024 guidance as provided in Q4 2023 earnings release dated Feb 7, 2024.
Oscar Health reports first-ever quarterly net income of $177.4M; revenue up 46% YoY
Q1 2024 net income of $177.4M ($0.62 diluted EPS) vs. net loss of $39.8M in Q1 2023.
Oscar Health posts FY2023 net loss $271M; 2024 adjusted EBITDA guidance positive $125M-$175M
FY2023 Direct and Assumed Policy Premiums $6.6B (-3% YoY); Premiums earned $5.7B (+47% YoY).
Oscar Health reaffirms FY2023 guidance and 2024 EBITDA target; no new figures
Reaffirms full year 2023 guidance as provided in Q3 2023 earnings release (Nov 7, 2023).
Oscar Health amends credit facility; maturity extended to Dec 2025, commitments cut to $115M
Third Amendment to Credit Agreement dated Dec 28, 2023 extends revolving loan maturity to Dec 28, 2025.
Deerfield and CEO Bertolini's foundation to buy 5M shares from selling shareholder
Deerfield will purchase 3,000,000 shares of Oscar Class A common stock.
Oscar Health Q3 net loss narrows to $65.7M; raises 2023 EBITDA outlook; new +Oscar deal
Net loss of $65.7M vs $193.5M loss YoY; Adjusted EBITDA loss of $20.3M vs $159.8M loss YoY.
Oscar Health CEO to present at Morgan Stanley conference; reaffirms FY2023 outlook
CEO Mark T. Bertolini to present at Morgan Stanley 21st Annual Global Healthcare Conference on Sept 11, 2023.
Net loss of $15.4M improved $96.7M YoY; Adjusted EBITDA $35.6M vs -$75.8M YoY.
Ten director nominees elected; each received >720M votes FOR, broker non-votes ~32M.
Interim CFO Sankaran to exit Aug 31; Oscar Health reaffirms 2023 outlook
CFO Siddhartha Sankaran will step down as interim CFO on Aug 31, 2023 after Q2 Form 10-Q filing.
Oscar Health Q1 net loss narrows to $39.6M; adjusted EBITDA turns positive at $51.1M
Premiums earned up 50% YoY to $1.4B; Direct & Assumed Policy Premiums $1.7B (+2% YoY).
Oscar Health appoints Mark Bertolini CEO; Schlosser moves to President of Technology
Mark Bertolini (ex-Aetna CEO) becomes CEO and board member effective April 3, 2023; Mario Schlosser transitions to President of Technology.
Oscar Health discloses no deposits, investments, or debt at failed Silicon Valley Bank
Oscar Health confirms it holds no deposits at Silicon Valley Bank (SVB).
Oscar Health reports FY 2022 net loss $610M; guides 2023 to near breakeven adjusted EBITDA
Full-year 2022 premiums earned $3.9B, up 111% YoY; Direct & Assumed Policy Premiums $6.8B, up 99%.
Oscar Health reaffirms FY2022 guidance, 2023 profitability target at JPM Conference
Reaffirms full-year 2022 guidance per Nov 8, 2022 press release.
Oscar Health director Charles E. Phillips Jr. resigns effective Dec 31, 2022
Charles E. Phillips Jr. notified the board on Dec 7, 2022 of his resignation.
Oscar Health expands board to 10, appoints Laura Lang and Bill Gassen as independent directors
Board size expanded from 8 to 10; appointments effective December 7, 2022.
Membership of 1,075,445 as of Sep 30, 2022, up 81% YoY; premiums earned $954M, up 116% YoY.
Oscar Health to reaffirm FY2022 guidance at two healthcare conferences
Company will present at Wells Fargo Healthcare Conference on Sep 8 and Morgan Stanley Global Healthcare Conference on Sep 12.
Oscar Health announces termination of services agreement with Health First effective Jan 1, 2023
Health First intends to terminate agreement with Oscar Health's +Oscar business, effective as early as Jan 1, 2023.
Oscar Health Q2 2022: revenue up 88% YoY to $995M, net loss widens to $112M; reaffirms FY22 outlook
Membership 1,036,720 (+84% YoY); Direct & Assumed Premiums $1.7B (+101%).
Oscar Health shareholders elect eight directors, ratify auditor, back annual say-on-pay
All eight director nominees elected with >728M votes FOR each; broker non-votes 45M.
Oscar Health Q1 membership up 98% to 1.07M; net loss narrows to $77M
Direct and Assumed Policy Premiums $1.68B (+104% YoY); Premiums earned $955M (+159% YoY).
Director Teri List resigns from Oscar Health board; Vanessa Wittman appointed Audit Committee Chair
Teri List resigned effective April 8, 2022, to pursue another board opportunity; no disagreement with the company.
Oscar Health to host virtual investor day on March 25, reaffirming FY2022 guidance
Investor day scheduled for March 25, 2022, at 9:00 a.m. ET; live webcast on IR website.
Oscar Health reaffirms FY2022 guidance at Cowen conference
Company reconfirms full-year 2022 guidance issued on Feb 10, 2022; no new financial metrics provided.
Mr. Schlosser’s transition from President of Technology and Chief Technology Officer of the Company to Co-Founder & Advisor to the CEO.
appointed Janet Liang as EVP and President of Oscar Insurance, effective February 24, 2025.
Steven Wolin resigned as EVP and Chief Operating Officer of the Company, effective as of February 5, 2025.
Alessandrea Quane, the Company’s EVP, Chief Insurance Officer, will cease serving in this role effective as of February 24, 2025 and her employment with the Company and Oscar Management Corporation (“OMC”) will terminate effective as of March 3, 2025.
Effective August 14, 2023, R. Scott Blackley will become the Company’s Chief Financial Officer (“CFO”).
Mr. Siddhartha Sankaran will remain CFO through that date.
On May 26, 2023, Oscar Health, Inc. (the “Company”) and Siddhartha Sankaran agreed that Mr. Sankaran will conclude his role as the Company’s Interim Chief Financial Officer as of August 31, 2023
Mark T. Bertolini will join the Company as Chief Executive Officer and a member of the Company’s Board of Directors
Co-founder Mario Schlosser will move into the role of President of Technology
On December 7, 2022, Charles E. Phillips, Jr. notified the Board of Directors (the “Board”) of Oscar Health, Inc. (the “Company”) of his decision to resign from the Board, effective as of December 31, 2022.
On December 6, 2022, the Board of Directors (the “Board”) of Oscar Health, Inc. (the “Company”) increased the size of the Board from a total of eight directors to ten directors and appointed Ms. Laura Lang and Mr. Bill Gassen to the Board, effective as of December 7, 2022
On December 6, 2022, the Board of Directors (the “Board”) of Oscar Health, Inc. (the “Company”) increased the size of the Board from a total of eight directors to ten directors and appointed Ms. Laura Lang and Mr. Bill Gassen to the Board, effective as of December 7, 2022
Max materiality 0.90 · Median 0.50 · Most common event earnings